Ozempic for Heart Failure: Off-Label Evidence Summary

What FDA-Approved Indications Does Ozempic Actually Have?

Ozempic (semaglutide injection, 0.5 mg, 1 mg, and 2 mg doses) received FDA approval in December 2017 for improving glycemic control in adults with type 2 diabetes mellitus. A second indication, reducing the risk of major adverse cardiovascular events (MACE: non-fatal MI, non-fatal stroke, and CV death) in adults with T2D and established cardiovascular disease, was added based on the SUSTAIN-6 trial. Using Ozempic in heart failure patients who do not carry a T2D diagnosis is, by definition, off-label prescribing.

What the FDA Label Actually Says

The FDA prescribing information for Ozempic states the drug is indicated "as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus" and for "reducing the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease." Heart failure, whether HFpEF or HFrEF, appears nowhere in the approved labeling.

Why the Confusion With Wegovy Exists

Semaglutide also exists as Wegovy (2.4 mg subcutaneous weekly), which carries FDA approval for chronic weight management. The STEP-HFpEF trials used 2.4 mg, the Wegovy dose, not the 0.5 to 2.0 mg Ozempic dose range. Clinicians sometimes prescribe Ozempic off-label for heart failure partly because Wegovy faces persistent supply constraints and partly because the underlying molecule is identical. The dose difference matters clinically, and readers should keep that distinction in mind throughout this article.

The STEP-HFpEF Trials: What the Evidence Actually Shows

The most direct randomized evidence comes from two phase 3 trials: STEP-HFpEF and STEP-HFpEF DM.

STEP-HFpEF (Patients Without Diabetes)

STEP-HFpEF enrolled 529 adults with heart failure with preserved ejection fraction (LVEF ≥45%) and obesity (BMI ≥30 kg/m²) who did not have type 2 diabetes. Participants received semaglutide 2.4 mg or placebo subcutaneously once weekly for 52 weeks. Results, published in the New England Journal of Medicine in August 2023, showed the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS) improved by a mean of 16.6 points in the semaglutide group versus 8.7 points with placebo, a between-group difference of +7.8 points (P<0.001) [1]. Body weight fell by 13.3% versus 2.6% with placebo. Six-minute walk distance improved by 21.5 meters more than placebo (P<0.001) [1].

STEP-HFpEF DM (Patients With Diabetes)

STEP-HFpEF DM replicated the design in 616 adults with HFpEF and coexisting type 2 diabetes. Published simultaneously in the New England Journal of Medicine, this trial showed a KCCQ-CSS improvement of +13.7 points versus +6.4 points with placebo, a between-group difference of +7.3 points (P<0.001) [2]. Weight loss was attenuated compared to the non-diabetic trial at -9.8% versus -3.4%, which is consistent with how GLP-1 receptor agonists generally perform in people with diabetes. The 6-minute walk distance improvement was +14.3 meters versus placebo [2].

Pooled Analysis Findings

A pre-specified pooled analysis of both STEP-HFpEF trials (N=1,145) confirmed consistent benefits across KCCQ-CSS, body weight, 6-minute walk distance, and a composite hierarchical endpoint of CV death, HF events, and symptom change. Semaglutide also reduced C-reactive protein by roughly 30% more than placebo, suggesting an anti-inflammatory mechanism beyond simple weight loss [3]. The pooled data were published in JACC: Heart Failure in 2024 and are available via PubMed.

Does the Evidence Apply to Ozempic's 0.5 to 2.0 mg Dose Range?

This is the central clinical question for off-label prescribing. The short answer: the evidence is indirect for Ozempic doses below 2.4 mg, and no randomized trial has tested Ozempic 0.5 to 2.0 mg specifically in heart failure as a primary endpoint study.

Pharmacological Rationale for Dose Extrapolation

Semaglutide at all doses activates the same GLP-1 receptor with the same mechanism. Higher doses produce greater receptor occupancy, more weight loss, and likely greater downstream cardiovascular benefit. The SUSTAIN-6 trial, which tested semaglutide 0.5 mg and 1.0 mg in 3,297 adults with T2D and high CV risk, showed a 26% relative risk reduction in MACE compared to placebo (HR 0.74; 95% CI 0.58 to 0.95; P<0.001 for non-inferiority) [4]. That trial was not designed to assess heart failure outcomes as a primary endpoint, but it did show directionally favorable trends for heart failure hospitalization.

The Dose-Response Gap

The 2.4 mg Wegovy dose produces roughly 15% body weight loss in non-diabetic patients. The 2.0 mg Ozempic dose produces approximately 9.6% weight loss based on SUSTAIN-11 data [5]. Because a meaningful portion of the HFpEF benefit in STEP-HFpEF is attributable to weight reduction, reducing cardiac filling pressures, improving diastolic function, and lowering inflammatory burden, a lower weight-loss effect at 2.0 mg may translate to a proportionally smaller HF benefit. No head-to-head data exist.

What "GRADE Moderate" Actually Means Here

Applying GRADE criteria to off-label Ozempic use in HFpEF: the evidence from STEP-HFpEF is rated Moderate for semaglutide 2.4 mg (two well-designed RCTs, consistent results, low risk of bias). Downgrading to Low for the 0.5 to 2.0 mg Ozempic dose range is appropriate because of indirectness, the dose tested in trials is not the dose being prescribed off-label. Clinicians and patients should understand they are extrapolating from adjacent evidence, not applying a direct result.

Semaglutide in Heart Failure With Reduced Ejection Fraction (HFrEF)

HFrEF evidence is thinner and more cautionary. Earlier GLP-1 agonist trials in HFrEF signaled potential harm. The FIGHT trial (liraglutide in 300 patients with HFrEF, LVEF <40%) showed no benefit on clinical stability and a non-significant trend toward worse outcomes in the most severe patients [6]. Semaglutide was not tested in that trial, but the shared mechanism raised concern.

The ATLAS Trial and Ongoing Research

The ATLAS trial (NCT05026424), currently enrolling, is examining semaglutide 2.4 mg specifically in HFrEF patients with obesity. Results are expected in 2026. Until that data is available, off-label Ozempic use in HFrEF should be considered Low-quality evidence at best and approached with considerable caution, particularly in patients with LVEF below 35%.

Why HFrEF and HFpEF Differ Mechanistically

HFpEF is driven heavily by obesity, metabolic inflammation, and elevated filling pressures, conditions that GLP-1 agonists address directly. HFrEF involves myocardial contractile dysfunction where the relationship between weight loss and cardiac output is less straightforward. Weight loss in a cachectic or borderline-compensated HFrEF patient may worsen outcomes, not improve them. This mechanistic distinction is why cardiologists are substantially more cautious about GLP-1 use in HFrEF than in HFpEF.

Cardiovascular Outcome Trials: Context From SUSTAIN-6 and SELECT

Two additional large trials inform how to think about semaglutide's cardiovascular profile.

SUSTAIN-6

SUSTAIN-6 enrolled 3,297 adults with T2D at high cardiovascular risk and randomized them to semaglutide 0.5 mg or 1.0 mg versus placebo for 104 weeks. The primary MACE endpoint showed HR 0.74 (95% CI 0.58 to 0.95) [4], establishing cardiovascular safety and superiority at doses overlapping with Ozempic's approved range. Heart failure hospitalization was not a primary endpoint, but the directional signal was favorable.

SELECT Trial

SELECT (N=17,604) tested semaglutide 2.4 mg in adults with established cardiovascular disease and obesity but without diabetes. Published in the New England Journal of Medicine in November 2023, SELECT showed a 20% relative risk reduction in MACE (HR 0.80; 95% CI 0.72 to 0.90; P<0.001) [7]. Heart failure hospitalization was reduced by 18% (HR 0.82; 95% CI 0.71 to 0.96) as a secondary endpoint [7]. These are Wegovy-dose data, but they reinforce the biological plausibility of cardiovascular benefit with the semaglutide molecule.

Current Guideline Positions on GLP-1 Agonists in Heart Failure

The 2022 AHA/ACC Guideline for the Diagnosis and Management of Heart Failure does not recommend GLP-1 receptor agonists for heart failure treatment. The guideline notes that liraglutide showed potential harm in HFrEF and states: "In patients with HF, GLP-1 RAs have not been shown to improve clinical outcomes and may be harmful in HFrEF" [8]. This statement predates the STEP-HFpEF publications and reflects the evidence base available in early 2022.

What Guideline Updates Are Expected

The ACC and AHA issue "focused updates" when major trial data changes practice. Given STEP-HFpEF and SELECT, a focused update specifically addressing GLP-1 agonists in HFpEF is anticipated. The European Society of Cardiology's 2023 guidelines on diabetes and cardiovascular disease acknowledged semaglutide's CV mortality reduction and weight benefit but stopped short of a formal HF indication recommendation, citing the need for longer-term HFpEF outcome data [9].

Where the 2022 AHA/ACC Guideline Leaves Clinicians

For now, prescribing Ozempic off-label for heart failure requires the clinician to document the evidence base, confirm the patient has coexisting conditions that might justify the prescription (T2D, obesity, established CVD), and engage in shared decision-making. The 2022 guidelines' statement on GLP-1 RAs specifically cites the HFrEF context; the language does not unambiguously extend to HFpEF with obesity.

Safety Considerations Specific to Heart Failure Patients

Heart failure patients represent a population with elevated baseline risk, multiple comorbidities, and polypharmacy, all of which shape how Ozempic's side-effect profile plays out clinically.

Gastrointestinal Side Effects and Volume Status

Nausea, vomiting, and diarrhea occur in 15 to 44% of patients on semaglutide depending on dose and titration speed [10]. In a compensated heart failure patient on loop diuretics, GI fluid losses can precipitate dehydration and electrolyte disturbances that may destabilize cardiac status. Slow titration, starting at 0.25 mg weekly for four weeks before advancing, reduces GI burden and should be standard practice in this population.

Muscle Mass and Cardiac Cachexia Risk

GLP-1 agonist-associated weight loss includes a lean mass component. In the STEP-1 trial (N=1,961), roughly 39% of total weight lost was lean mass [11]. Cardiac cachexia is already an independent predictor of mortality in HF. Prescribers should monitor body composition and consider resistance exercise co-prescription to preserve muscle mass during semaglutide therapy.

Contraindications That Apply Universally

Ozempic carries a boxed warning for thyroid C-cell tumors based on rodent data. It is contraindicated in personal or family history of medullary thyroid carcinoma or MEN2. For heart failure patients specifically, NYHA Class IV status was an exclusion criterion in STEP-HFpEF, meaning no randomized safety data exist for the most severe HF patients. Off-label use in NYHA Class IV carries GRADE Very Low evidence and is not supported by available trial data.

Practical Off-Label Prescribing Considerations

Dose Selection and Titration

Ozempic is available as 0.25 mg (starter dose only), 0.5 mg, 1.0 mg, and 2.0 mg weekly subcutaneous injections. The closest approximation to STEP-HFpEF evidence uses 2.0 mg, the maximum approved Ozempic dose, though this remains below the 2.4 mg trial dose. Titrating to 2.0 mg over 16 to 20 weeks (0.25 mg for 4 weeks, 0.5 mg for 4 weeks, 1.0 mg for 4 weeks, then 2.0 mg) mirrors the SUSTAIN-11 titration schedule [5].

Patient Selection

The profile closest to STEP-HFpEF enrollment criteria includes: HFpEF (LVEF ≥45%), NYHA Class II, III symptoms, BMI ≥30 kg/m², and a coexisting indication (T2D or obesity) that supports at least one FDA-approved use of semaglutide. Patients without any FDA-approved indication for semaglutide who are prescribed it solely for heart failure face the greatest insurance and ethical complexity.

Monitoring Parameters

Clinicians prescribing off-label in this context should track: KCCQ scores at baseline, 12 weeks, and 24 weeks; body weight and estimated lean mass; BNP or NT-proBNP; serum electrolytes every four to six weeks during titration; and renal function. Any worsening of HF symptoms, new lower-extremity edema, or rise in BNP above baseline warrants holding the drug and reassessing.

Insurance, Prior Authorization, and Access

Commercial insurers almost universally deny Ozempic for heart failure as a standalone indication. Coverage is approved when T2D is the primary diagnosis. For patients with HFpEF and coexisting obesity but no diabetes, Wegovy (2.4 mg) may be the more defensible prescription given that SELECT showed cardiovascular benefit at that dose in an obesity-without-diabetes population, and some payers now cover Wegovy for CVD risk reduction following the SELECT data and the August 2024 FDA label expansion for Wegovy to include MACE reduction [12].